Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions

Diagnostic Cytopathology

Volumn 17, Issue 2, 1997, Pages 115-120

  Delahaye, Mick ^a   Van der Ham, Frieda ^a   Van der Kwast, Theo H ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Adenocarcinoma; Cytology; Immunocytochemistry; Malignant mesothelioma; Serous fluid

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADENOCARCINOMA; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER CYTODIAGNOSIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; PLEURA EFFUSION; PLEURA METASTASIS; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; PERITONEAL NEOPLASMS; PLEURAL EFFUSION; PLEURAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030857231     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0339(199708)17:2<115::AID-DC6>3.0.CO;2-F     Document Type: Article

References (44)

1. Whitaker D, Shilkin K. Diagnosis of pleural malignant mesothelioma in life. A practical approach. J Pathol 1984;143:147-175.
2. Kwee WS, Veldhuizen RW, Alons CA, Morawetz F, Boon ME. Quantitative and qualitative differences between benign and malignant mesothelial cells in pleural fluid. Acta Cytol 1982;26:401-406.
3. Delahaye M, Hoogsteden HC, Van der Kwast Th. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. J Pathol 1991;165:137-143.
4. Tickman RJ, Cohen C, Varma VA, Fekete PS, DeRose PB. Distinction between carcinoma cells and mesothelial cells in serous effusions. Usefulness of immunohistochemistry. Acta Cytol 1990;34:491-496.
5. Cibas ES, Corson JM, Pinkus GS. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions. Hum Pathol 1987;18:67-74.
6. Nance KV, Silverman JF. Immunocytochemical panel for the identification of malignant cells in serous effusions. Am J Pathol 1991;95:867-874.
7. Guzman J, Bross KJ, Wurtemberger G, Costabel U. Immunocytology in malignant pleural mesothelioma, Expression of tumor markers and distribution of lymphocyte subsets. Chest 1989;95:590-595.
8. Maguire B, Whitaker D, Carrello S, Spagnolo D. Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens. Diagn Cytopathol 1994;10:130-134.
9. Shield PW, Callan JJ, Devine PL. Markers for metastatic adenocarcinoma in serous effusion specimens. Diagn Cytopathol 1994;11:237-245.
10. Delahaye M, Van der Kwast Th. Cytodiagnostic processing of serous fluids and its influence on the ability to diagnose malignant mesothelioma correctly. Acta Cytol (in press).
11. Martin SE, Moshin S, Thor A, Vilasi V, Chu EW, Schlom J. Identification of adenocarcinoma in cytospin preparations of effusions using monoclonal antibody B72.3. Am J Pathol 1986;86:10-18.
12. Dejmek A, Hjerpe A. Carcinoembryonic antigen-like reactivity in malignant mesothelioma. A comparison between different commercially available antibodies. Cancer 1994;73:464-469.
13. Elias JM, Margiotta M, Gabore D. Sensitivity and detection efficiency of the peroxidase antiperoxidase (PAP), avidin-hiotin peroxidase complex (ABC), and peroxidase-labeled avidin-biotin (LAB) methods. Am J Clin Pathol 1989;92:62-67.
14. Li CY, Laczano-Villareal O, Pierre RV, Yam LT. Immunocytochemical identification of cells in serous effusion. Technical consideration. Am J Pathol 1987;88:696-706.
15. Stirling JW, Henderson DW, Spagnolo DV, Whitaker D. Unusual granular reactivity for carcinoembryonic antigen in malignant mesothelioma I (letter to the editor). Hum Pathol 1990;21:678-679.
16. Ordonez NG. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcmoma. Am J Surg Palhol 1989;13:276-291.
17. Szpak CA, Johnston WW, Roggli V, et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am J Pathol 1986;122:252-260.
18. Permanetter W, Wiesinger H. Immunohistochemical study of Iysozyme, alpha-1 anti-chymotrypsin, tissue polypeptide antigen, keratin and carcinoembryonic antigen in effusion sediments. Acta Cytol 1987;3:104-112.
19. Van der Kwast Th, Delahaye M, Fleury J. Cytological diagnosis of malignant mesothehoma. In: Mesothelial cells and mesothelioma. New York: Marcel Dekker, 1993:121-167.
20. Gosh AK, Butler EB. Immunocytochemical staining reactions of anti-carcinoembryonic antigen, Ca and anti-human milk fat globule monoclonal antibodies on benign and malignant exfoliated cells. J Clin Pathol 1987;40:1424-1427.
21. Sehested M, Ralfkjaer E, Ramussen J. Immunoperoxidase demonstration of carcinoembryonic antigen in pleural and peritoneal effusions. Acta Cytol 1983;27:124-127.
22. Croonen AM, Van der Valk P, Herman C, Lindeman J. Cytology, immunopathology and flow cytometry in the diagnosis of pleural and peritoneal effusions. Lab Invest 1988;58:725-732.
23. Mason MR, Berossian CWM, Fahey CA. Value of immunocytochemistry in the study of malignant effusions. Diagn Cytopathol 1987;3:215-221.
24. Lauritzen AF. Diagnostic value of monoclonal antibody B72.3 in detecting adenocarcinoma cells in serous effusions. APMIS 1989;97:761-766.
25. Ruitenbeek T, Gouw ASH, Poppema S. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells. Arch Pathol Lab Med 1994;118:265-269.
26. Berendsen HH, de Leij L, Postmus PE, et al. Small cell lung cancer. Tumor cell phenotype detected by monoclonal antibodies and response to chemotherapy. Chest 1987;91:11S-12S.
27. De Leij L, Postmus PE, Poppema S, Elema JD, The TH. The use of monoclonal antibodies for the pathological diagnosis of lung cancer. In: Hansen HH, ed. Lung cancer: basic and clinical aspects. Boston: Martinus Nijhoff, 1986:31-48.
28. Edwards C, Oates J. OV632 and MOC31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin embedded material. J Clin Pathol 1995;48:626-630.
29. Wirth PR, Legier J, Wright GL. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Cancer 1991;67:655-662.
30. Dejmek A, Hjerpe A. Immunohistochemical reactivity in mesothelioma and adenocarcinoma: a stepwise logistic regression analysis. APMIS 1994;102:255-264.
31. Robb JA. Mesothelioma versus adenocarcinoma: false-positive CEA and LeuM1 staining due to hyaluronic acid (letter to the editor). Hum Pathol 1989;20:400.
32. Latza U, Niedobitek G, Schwarting R, Nekarda H, Stein H, Ber-Ep4: a new monoclonal antibody which distinguishes epithelia from mesothelia. J Clin Pathol 1990;43:213-219.
33. Stoop JA, Hendriks GM, Berends D. Identification of malignant cells in serous effusions using a panel of monoclonal antibodies Ber-EP4, MCA-b-12 and EMA. Cytopathology 1992;3:297-302.
34. Robinson RJ, Royston D. Comparison of monoclonal antibodies AUA1 and Ber-EP4 with anti-CEA for detecting carcinoma cells in serous effusions and distinguishing them from mesothelial cells. Cytopathology 1993;4:267-271.
35. Diaz-Arias AA, Loy TS, Bickel JT, Chapman RK. Utility of Ber-EP4 in the diagnosis of adenocarcinoma in effusions: an immunocytochemical study of 232 cases. Diagn Cytopathol 1993;9:516-521.
36. Kuhlmann L, Berghauser KH, Schaeffer R. Distinction of mesothelioma from carcinoma in pleural effusions. An immunocytochemical studs on routinely processed cytoblock preparations. Path Res Pract 1991;187:467-471.
37. Sheibani K, Shin SS, Kezirian J, Weiss LM. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Am J Surg Pathol 1991;15:779-784.
38. Gaffey MJ, Mills SE, Swanson PE, Zarbo RJ, Wick M. Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors and malignant mesotheliomas. Am J Surg Pathol 1992;16:3-9.
39. De Angelis M, Buley ID, Heryet A, Gray W. Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4. Cytopathology 1992;3:111-117.
40. Johnston WW, Szpak CA, Lottich SC, Thor A, Schlom J. Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to the diagnosis of adenocarcinoma in human effusions. Cancer Res 1985;45:1894-1900.
41. Ernst CS, Atkinson B, Chianese D, et al. Differential diagnosis between mesotheliomas and metastatic adenocarcinomas using monoclonal antibodies against gastrointestinal carcinoma antigen and stage specific embryonic antigen. Appl Pathol 1986;4:115-124.
42. Brown RW, Clark GM, Tandon AK, Allred DC. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol 1993;24:347-354.
43. Frisman DM, McCartney WF, Schleiff P, Buckner SB, Nocito JD, O'Leary TJ. Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinoma from mesothelial proliferations. Mod Pathol 1993;6:179-184.
44. Stevens MW, Leong ASY, Fazzalari ML, Dowling KD, Henderson DW. Cytopathology of malignant mesothelioma. A stepwise logistic regression analysis. Diagn Cytopathol 1992;8:33-341.